Abstract:Ziqin Zhao, 1 Shuhui Dong, 1 Yong Yang, 1 Haibo Yin, 1 Guangyi Xiong, 1 Jianxiong Ma 2 1 Department of Pathology, Tianjin Hospital, Tianjin University, Tianjin, People's Republic of China; 2 Institute of Orthopaedic Surgery, Tianjin Hospital, Tianjin University, Tianjin, People's Republic of China Correspondence: Jianxiong Ma, Institute of Orthopaedic Surgery, Tianjin Hospital, Tianjin University, Tianjin, People's Republic of China, Email Introduction: Chondrocyte degeneration and senescence are characteristics of osteoarthritis (OA) and other joint degenerative diseases, and ferroptosis has been observed to regulate the development of OA. However, the role of the N 6 -methyladenosine (m 6 A) modification in OA ferroptosis remains unclear. Methods: This study performed series of assays to investigate the function of the m 6 A reader IGF2BP1 in OA ferroptosis, including m 6 A quantitative analysis, Iron (Fe 2+ ) release analysis, Malondialdehyde (MDA) measurement, lipid peroxidation (ROS) detection and Glutathione (GSH) measurement. The molecular interaction and mechanism analysis was performed by Luciferase reporter assay, mRNA stability analysis and RNA immunoprecipitation (RIP) assay. Results: These results indicate that IGF2BP1 is upregulated in IL-1β-induced chondrocytes. Functionally, IGF2BP1 silencing represses ferroptosis, including iron (Fe 2+ ) accumulation, malondialdehyde, and reactive oxygen species (ROS). Mechanistically, among the potential downstream targets, matrix metalloproteinase-3 (MMP3) was observed to harbor a significant m 6 A modified site in the 3'-UTR. IGF2BP1 combines with MMP3 through the binding of m 6 A sites, thereby enhancing MMP3 mRNA stability. Discussion: In conclusion, our findings revealed the functions and mechanisms of m 6 A regulator IGF2BP1 in OA chondrocyte's ferroptosis, providing a novel target for OA treatment. Keywords: osteoarthritic cartilage, IGF2BP1, ferroptosis, MMP3 Osteoarthritis (OA) is the most common musculoskeletal disease and is associated with an extremely high disability rate and a decreased quality of life in the elderly population. 1 The clinical symptoms of OA include joint swelling, joint stiffness, joint pain, and loss of joint function, which induce difficulties in daily activities. 2 Currently, there are few effective treatments for OA other than total knee replacement in patients with advanced OA. 3 For patients with early OA, the treatment is to reduce joint wear and relieve pain. 4 Furthermore, nonsteroidal anti-inflammatory drugs and surgical interventions are also applied to OA treatment, which have some side effects. 5 Therefore, it is necessary to identify novel molecular targets for OA pathophysiology and prevention. N 6 -methyladenosine (m 6 A) is an important ubiquitous internal modification of eukaryotic RNA that plays a critical role in physiological functions. 6 The m 6 A modification has been shown to modify numerous aspects of pathophysiological processes, including RNA metabolism, export, translation, and decay. Three key enzymes regulate the m 6 A modification, including "writer" proteins (METTL3, METTL14, KIAA1429, WTAP, etc.), "eraser" proteins (ALKBH5, FTO) and "reader" proteins (YTHDF1/2/3 YTHDC1, IGF2BP1/2/3, etc.). In OA pathophysiology, m 6 A levels in clinical OA samples are higher than those in healthy samples. 7 Currently, key m 6 A modification enzymes are known to act as risk factors for OA, or might provide potential therapeutic targets for OA treatment. For example, METTL3 is highly expressed in clinical samples from patients with OA, and low METTL3 expression inhibits chondrocyte pyroptosis. 7 Ferroptosis is an iron-dependent subtype of programmed cell death (iron-dependent type) involved in oxidative stress-induced cell death. 8–10 Several studies have demonstrated that redox imbalance plays an important role in OA development. Previous studies have indicated that iron can trigger bovine articular cartilage degeneration by enhancing the release of sulfated glycosaminoglycan. For example, chondrocytes undergo inflammation and iron overload that can trigger ferroptosis. Recent findings have indicated that ferroptosis plays an important role in the occurrence and development of OA. For instance, the ferroptosis-related genes LPCAT3 and PGD, which have both been identified as effective diagnostic biomarkers for OA patients, are decreased in OA chondrocytes with an IL-1β-induced condition. 11 There was remarkable rele -Abstract Truncated-

D-mannose alleviates osteoarthritis progression by inhibiting chondrocyte ferroptosis in a HIF-2-dependent manner

D‐mannose alleviates osteoarthritis progression by inhibiting chondrocyte ferroptosis in a HIF‐2α‐dependent manner

Chondrocyte ferroptosis contribute to the progression of osteoarthritis

Deferoxamine alleviates chondrocyte senescence and osteoarthritis progression by maintaining iron homeostasis

Astaxanthin Attenuates Osteoarthritis Progression Via Inhibiting Ferroptosis and Regulating Mitochondrial Function in Chondrocytes.

SCD1 deficiency exacerbates osteoarthritis by inducing ferroptosis in chondrocytes

SCP2 Mediates the Transport of Lipid Hydroperoxides to Mitochondria in Chondrocyte Ferroptosis

Characteristics and Time Points to Inhibit Ferroptosis in Human Osteoarthritis

d-mannose attenuates lipopolysaccharide-induced osteolysis via CPT1A-Mediated lipid metabolic regulation in macrophages

Nesfatin-1 suppresses autophagy of chondrocytes in osteoarthritis via remodeling of cytoskeleton and inhibiting RhoA/ROCK signal pathway

Dehydroepiandrosterone and Experimental Osteoarthritis.

D-mannose Attenuates Bone Loss in Mice Via Treg Cell Proliferation and Gut Microbiota-Dependent Anti-Inflammatory Effects.

Single cell RNA-seq analysis identifies ferroptotic chondrocyte cluster and reveals TRPV1 as an anti-ferroptotic target in osteoarthritis

XJB-5-131 protects chondrocytes from ferroptosis to alleviate osteoarthritis progression via restoring Pebp1 expression

Inhibition of SAT1 alleviates chondrocyte inflammation and ferroptosis by repressing ALOX15 expression and activating the Nrf2 pathway

Moderate mechanical stress suppresses chondrocyte ferroptosis in osteoarthritis by regulating NF-κB p65/GPX4 signaling pathway

Unveiling the role of RhoA and ferroptosis in vascular permeability: Implications for osteoarthritis

Chondroprotective effects of bone marrow mesenchymal stem cell-derived exosomes in osteoarthritis

Ferroptosis in Osteoarthritis: Towards Novel Therapeutic Strategy

IGF2BP1 Bolsters the Chondrocytes Ferroptosis of Osteoarthritis by Targeting m6A/MMP3 Axis

Iron Overload Is Associated With Accelerated Progression of Osteoarthritis: The Role of DMT1 Mediated Iron Homeostasis